Navigation Links
NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer
Date:10/8/2007

BEDMINSTER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today the appointment of Brian O'Callaghan as senior vice president and chief commercial officer, effective October 15, 2007.

As a member of the NPS executive team, Mr. O'Callaghan will be responsible for managing the company's marketing and corporate and business development activities, including the commercial development of NPS's late-stage products and coordination of its joint-venture partnerships with other companies. He will report to Dr. Francois Nader, executive vice president and chief operating officer of NPS.

Mr. O'Callaghan joins NPS from Covance, a global clinical research organization, where he served as general manager of the cardiac safety and IVRS business units. Previously he was North American regional business unit head for infectious diseases and transplantation/immunology at Novartis, president of BioPartners GmbH, and held sales and marketing positions at Merck KGaA, Merck & Lipha Pharmaceuticals and Pfizer.

"Brian brings to NPS more than 15 years of experience in pharmaceutical sales, marketing, business development and general management," said Dr. Nader. "We welcome his contributions to the commercialization of our late-stage product candidates PREOS(R) and GATTEX(TM) and to the success of our earlier-stage corporate collaborations."

Mr. O'Callaghan has a master's degree in business administration from Henley College and a marketing degree from Cork Regional College/Marketing Institute of Ireland.

About NPS

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.

Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of October 8, 2007 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2007.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. ... in Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes ... back of my mind for years, but actually doing it might have been a while ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... issue of world hunger, and shares the simple and achievable answer. “The Land of ... member of the Fairview Missionary Church in Angola, Indiana where he works with the ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare ... four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs ... are an important part of the Administration’s effort to build a system that delivers ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the ... Congressional political games that circumvent health needs of over 30 million. Many interviews with ... anxieties and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... With the cold weather here, many people ... Snow blowers are efficient when clearing large amounts of snow, but they can be dangerous ... the U.S. Consumer Product Safety Commission for the proper use of snow blowers:, ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan 20, 2017 Research and Markets ... Analysis & Trends - Technology, Route Of Administration, End User - ... ... is poised to grow at a CAGR of around 7.8% over ... This industry report analyzes the global markets for Advanced ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver ... - 2024" report to their offering. ... The global clinical laboratory testing market ... Introduction of innovative solutions on the grounds of maximum efficiency and ...
(Date:1/20/2017)... 20, 2017  Ethicon Endo-Surgery, Inc. announced ... Products, Inc., a privately held medical device ... tools used in operating rooms worldwide. The ... advanced energy devices with Megadyne,s innovative portfolio ... forward in Ethicon,s goal to deliver the ...
Breaking Medicine Technology: